Kratom Research Institute

Research · 2026-11-16

Clinical review examines kratom toxicity and gaps in pain-product evidence

Source: Orthopedic Reviews

Why it matters

A narrative review of nonprescription pain products examines kratom-related dependence, possible drug interactions and reports of organ toxicity. It also explains why variable formulations and other drug exposures limit conclusions about the risks of a particular product.

The big picture

The paper reviews existing literature rather than testing kratom in a new clinical trial. Its kratom section distinguishes traditional whole-leaf preparations from concentrated extracts and products enriched with 7-hydroxymitragynine. Reported reasons for using kratom, such as pain relief or opioid withdrawal, do not establish treatment effectiveness.

Key findings

What they say

The authors write that respiratory-event reports often involve polysubstance exposure, which makes it difficult to determine kratom’s independent contribution. They also caution that seizure reports do not establish a definitive dose-response relationship.

Bottom line

This review supports asking patients about kratom products and other medications, while leaving major uncertainties about product-specific toxicity and treatment benefit unresolved.